Adicet Bio, Inc

Don’t miss the latest update on our ADI-270 oncology program!    VP, Nonclinical Development, Shon Green, Ph.D. presents data showing enhanced preclinical potency and persistence in multiple oncology models in an oral session at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, this week!   ADI-270, our first ever gamma delta 1 CAR T cell therapy candidate to enter clinical trials for solid tumors, was granted Fast Track Designation by the FDA earlier this year and is being studied in various solid tumors including renal cell carcinoma (RCC).   ADI-270 is an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70-positive cancers. CD70 is a compelling target due to its high expression in both solid and hematological malignancies.    We’re inspired to advance this novel program on behalf of patients. To learn more about participating in this #clinicaltrial, email clinicaltrials@adicetbio.com   #ASGCTAdvancing24 #CART #celltherapy #gammadelta #clinicaltrials #cancer #oncology #solidtumors #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf  

We are pleased to announce that FDA has granted clearance of an IND amendment to evaluate ADI-001 in two additional indications, Idiopathic Inflammatory Myopathy (IIM) and Stiff Person Syndrome (SPS)!   This acceptance builds on our recent momentum, expanding our efforts to six #autoimmune indications as we aim to bring our differentiated gamma delta T cell therapy candidates to more patients in need of new treatment options.    In addition to IIM and SPS, ADI-001 is also being studied in systemic #lupus erythematosus (#SLE), lupus nephritis (LN), systemic #sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV). With its safety profile, robust tissue trafficking and complete B cell depletion in peripheral blood and secondary lymphoid tissue (characteristics important in autoimmune treatment), ADI-001 is uniquely differentiated with the goal to bring durable remissions and provide an immune reset for various autoimmune conditions. We are inspired by the idea of bringing to #patients a potential paradigm shift in the treatment of autoimmune diseases. To learn more about participating in this #clinicaltrial, email clinicaltrials@adicetbio.com.   We also have updated biomarker data being presented in an oral session at #ACRConvergence2024 next month – be sure to tune into that, November 19! #CART #celltherapy #gammadelta #clinicaltrials #autoimmune #autoimmuneclinicaltrials #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

We are pleased to announce that we have activated clinical sites and are initiating enrollment for the Phase 1 trial of ADI-001 in autoimmune diseases!   This follows the U.S. Food and Drug Administration’s (FDA) decision to grant Fast Track Designation to ADI-001 for the treatment of relapsed/refractory class III or class IV #lupus nephritis (LN) and clearance from FDA to develop ADI-001 in four #autoimmune indications including LN, systemic lupus erythematosus (#SLE), systemic #sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV).   With its safety profile, robust tissue trafficking and complete B cell depletion in peripheral blood and secondary lymphoid tissue (characteristics important in autoimmune treatment), ADI-001 is uniquely differentiated with the goal to bring durable remissions and provide an immune reset for various autoimmune conditions. We are inspired by the idea of bringing to #patients a potential paradigm shift in the treatment of autoimmune diseases. To learn more about participating in this #clinicaltrial, visit https://lnkd.in/esC4winc or email clinicaltrials@adicetbio.com. #CART #celltherapy #gammadelta #clinicaltrials #autoimmune #autoimmuneclinicaltrials #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

Leading the way for cell therapy advancements in autoimmune indications, we’re pleased for our CSO, Dr. Blake Aftab to share data insights from our off-the-shelf #gammadelta CAR T cell program today at the #CARTCR2024 Summit! In a review of clinical biomarker data, the findings highlight ADI-001's robust tissue trafficking and complete B cell depletion in tissue, making it a potential best-in-class #allogeneic #celltherapy for the treatment of #autoimmune disease. We look forward to continuing to study ADI-001 in various autoimmune indications including #lupus nephritis (LN), systemic lupus erythematosus (#SLE), systemic sclerosis (SSc or #scleroderma) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (#AAV) To learn more about participating in this #clinicaltrial, visit https://lnkd.in/esC4winc or email clinicaltrials@adicetbio.com #CART #autoimmune #autoimmuneclinicaltrials #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

Celebrating our colleagues Shon Green (Vice President, Nonclinical Development) and Ekatherina Goryachikov (Vice President, Clinical Operations) who helped facilitate a workshop on advancing #celltherapy #clinicaltrials for #autoimmune diseases at this week’s #CARTCR2024 Summit! Coming together to fully realize the bright future for #celltherapies in autoimmune disease, these leaders charted a course to evolve #research, regulatory, and clinical operations strategies. The commitment to delivering these medicines to #patients with #lupus nephritis, #SLE, #scleroderma, systemic sclerosis, ANCA-associated #vasculitis and other autoimmune conditions was palpable. To learn more about participating in a #clinicaltrial, visit https://lnkd.in/esC4winc or email clinicaltrials@adicetbio.com #CART #autoimmuneclinicaltrials #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

Did you hear? Adicet Bio, Inc Chief Scientific Officer, Dr. Blake Aftab, Vice President of Nonclinical Development, Dr. Shon Green and Vice President of Clinical Operations, Ekatherina Goryachikov are creating impact at this week’s 9th Annual #CARTCR Summit! Together with top minds in the industry, they’re leading sessions to usher in the next frontier in #celltherapy research and development. #CART  #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

Adicet Bio, Inc is pleased to welcome Dr. Lloyd Klickstein to our Board of Directors!   Dr. Klickstein’s expertise in rheumatology and immunology, proven track record in drug development, and scientific knowledge of our gamma delta T cell platform will be very valuable as we progress our autoimmune programs across multiple indications.    We look forward to working with Dr. Klickstein to develop a differentiated pipeline in our mission to deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases and cancer!   #celltherapy #autoimmune #oncology #gammadelta #CART #executiveleadership #biotechinvesting #biotech #biotechnology

Adicet is pleased to report #secondquarter #financial and business updates underscoring a strong balance sheet and significant clinical development progress across our #autoimmune and #oncology programs.    Following recent FDA Investigational New Drug (IND) clearances, ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (#SLE), systemic sclerosis (#SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (#AAV).    Adicet also received fast track designation for ADI-001 in #lupus nephritis and initiated startup activities at multiple clinical sites with plans to commence #enrollment in its Phase 1 #clinicaltrial of ADI-001 in LN. If you are a #researcher, #patient or #caregiver looking for a lupus nephritis #clinicaltrial, please email clinicaltrials@adicetbio.com.   The Company also recapped its IND clearance for ADI-270 in the treatment of patients with relapsed/refractory renal cell carcinoma (RCC), the most common type of #kidneycancer.   Check out the full press release on the Adicetbio.com Investors Page. This clinical development progress across the Adicet #pipeline underscores the unique potential of our #gammadelta 1 CAR T cell platform in both autoimmune diseases and #solidtumors.   We look forward to continuing to deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases and cancer!

We’re pleased for Adicet’s Head of Clinical Operations, Ekatherina Goryachikov to share best practices for designing and running a CAR T cell therapy in autoimmune and oncology indications during a featured session at the 5th Annual Gamma Delta T Cell Therapies Summit!   As a track leader, she also facilitated a series of sessions on techniques to develop gamma delta T cells at a commercial scale.    #CART #celltherapy #gammadelta #gammadeltaconference #clinicaltrials #autoimmune #autoimmuneclinicaltrials #cancerresearch #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

Dr. Francesco Galimi, MD PhD, Adicet Chief Medical Officer, leads several sessions this week at the Gamma Delta T Cell Therapies Summit! Along with other C-suite execs, Dr. Galimi reflects on the industry advances and key insights from 2023 and anticipates the path ahead in 2024 via a review of the latest clinical updates, investor trends and opportunities for gamma delta T cells to drive solid tumor and autoimmune success. Tomorrow, he kicks off the conference after the Chair’s Opening Remarks with a Clinical Overview of Adicet’s lead product candidate ADI-001 in autoimmune diseases and cancer, then participates in a Fireside chat reviewing the unique promise of gamma delta T cell therapies for autoimmune diseases. #CART #celltherapy #gammadelta #gammadeltaconference #clinicaltrials #autoimmune #autoimmuneclinicaltrials #cancerresearch #leadership #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf